We could not find any results for:
Make sure your spelling is correct or try broadening your search.
India Globalization Capital Inc is an investment holding company. The company's operating segment includes Infrastructure and Life Sciences. It generates maximum revenue from the Life Sciences segment. The Infrastructure Business segment involves the execution of construction contracts, the rental o... India Globalization Capital Inc is an investment holding company. The company's operating segment includes Infrastructure and Life Sciences. It generates maximum revenue from the Life Sciences segment. The Infrastructure Business segment involves the execution of construction contracts, the rental of heavy construction equipment, and the purchase and resale of physical commodities used in infrastructure. The Life Sciences Segment includes biopharmaceuticals and Over the Counter Products Geographically, it derives a majority of revenue from Hong Kong and also has a presence in India. Show more
- Study Achieves Secondary End Point: Demonstrates Clinical Reduction, approaching statistical significance, at Week Two, in Agitation in Dementia due to Alzheimer’s - IGC Pharma, Inc. (“IGC...
IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the...
IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”...
- Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation Associated with Dementia Due to Alzheimer’s...
IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice President, will participate in a fire chat at the...
IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman...
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced the results of preclinical studies investigating its drug candidate TGR-63 as a treatment for...
IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the...
IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024). Q3 FY2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1106 | -20.5347196435 | 0.5386 | 0.65 | 0.413 | 1256092 | 0.52732407 | CS |
4 | 0.02 | 4.90196078431 | 0.408 | 0.9099 | 0.3751 | 1731083 | 0.57025848 | CS |
12 | 0.151 | 54.5126353791 | 0.277 | 0.9099 | 0.27 | 950994 | 0.47764173 | CS |
26 | 0.1301 | 43.6723732796 | 0.2979 | 0.9099 | 0.2501 | 575350 | 0.43400689 | CS |
52 | 0.078 | 22.2857142857 | 0.35 | 0.9099 | 0.2501 | 388734 | 0.4132396 | CS |
156 | -1.192 | -73.5802469136 | 1.62 | 4.65 | 0.2501 | 1078504 | 1.77243878 | CS |
260 | -1.112 | -72.2077922078 | 1.54 | 4.65 | 0.2501 | 1933211 | 1.95505161 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions